Record Q2 2026 net revenues and active patients were driven by strong growth across all product lines, especially in the U.S., Germany, and Japan. Gross margin improved to 78%, and full-year revenue guidance was raised to $710–$725 million, with a clear path to profitability.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.